Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Danoprevir (RG7227) 是具有口服活性的NS3/4A 蛋白酶抑制剂,IC50值为 0.29 nM。它抑制 HCV 基因型 1a, 1b, 4, 5, 6 (IC50s=0.2-0.4 nM) 和 2b, 3a (IC50s=1.6, 3.5 nM)。它也是SARS-CoV 3CLpro 的抑制剂,IC50为 0.05 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 410 | 现货 | ||
5 mg | ¥ 997 | 现货 | ||
10 mg | ¥ 1,580 | 现货 | ||
25 mg | ¥ 2,710 | 现货 | ||
50 mg | ¥ 3,950 | 现货 | ||
100 mg | ¥ 5,750 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,510 | 现货 |
产品描述 | Danoprevir (RG7227) is a peptidomimetic inhibitor of the NS3/4A protease(IC50=0.2-3.5 nM) of hepatitis C virus (HCV). |
靶点活性 | HCV NS3/4A protease:0.2 nM-3.5 nM |
体内活性 | In rats or monkeys,Danoprevir (30 mg/kg) was administered. |
激酶实验 | Continuous fluorescent resonance energy transfer (FRET) assay: The assay buffer contains 25 μM NS4A peptide, 50 mM Tris-HCl, pH 7.5, 15% (vol/vol) glycerol, 0.6 mM lauryldimethylamine N-oxide, 10 mM dithiothreitol, and 0.5 μM fluorescein/QXL520-labeled FRET substrate {Ac-DE-Dap(QXL520)-EE-Abu-ψ-[COO]-AS-Cys(5-FAMsp)-NH2}. K2040 enzyme (50 pM) is added to initiate the reaction. Reactions are set up in black 96-well plates, and fluorescence data is collected. Control reactions lacking inhibitors and enzyme are included. Initial rates are calculated from the linear phase of the reaction (up to 1 hour) and are used to obtain IC50. Recovery of activity from preformed Danoprevir-NS3/4A complex is assessed by preincubating 10 nM NS3/4A with a two-fold excess of Danoprevir in 1× assay buffer for 15 min, followed by a rapid 200-fold dilution of the preformed complex into assay buffer containing substrate. A control reaction with the same final conditions without preincubation of NS3/4A and Danoprevir is initiated by the addition of enzyme to an otherwise-complete reaction mixture. Additional control reactions lack either Danoprevir or NS3. The progress of the reactions is followed over 5 hours. |
细胞实验 | Serially diluted Danoprevir is added to Huh7 cells harboring the K2040 replicon 1 day after cell plating. For antiviral assays, after a 48-hour incubation, intracellular RNA is extracted, and the level of HCV replicon RNA is quantified by reverse transcription (RT)-PCR assay with the primers (5'-CACTCCCCTGTGAGGAACTACTG-3' and 5'-AGGCTGCACGACACTCATACT-3') and a probe (5'-6-FAM-CTTCACGCAGAAAGCGTCTAGCCATGG-MGBNFQ-3' using an ABI Prism 7900 sequence detection system. Here, FAM is 6-carboxyfluorescin and MGBNFQ is a molecular-groove binding non-fluorescence quencher specific to the HCV 5' untranslated region. Single-tube reactions are performed using the TaqMan Gold RT-PCR kit. Triplicate reactions for the RNA standards and samples are performed in 50 μL with 5 μL intracellular RNA (50 ng). RT is carried out at 48 °C for 30 min followed by 10 min at 95 °C. The PCR is run as follows: 15 seconds at 95 °C and 1 min at 60 °C for 40 cycles. Each RNA concentration is determined in triplicate. The absolute concentration of replicon RNA is calculated based on its signal relative to that of a standard curve generated by known concentrations of an in vitro-transcribed RNA corresponding to a genotype 1b 5' untranslated region. Replicon levels in the presence of Danoprevir are fitted to a four-parameter logistic function to obtain EC50.(Only for Reference) |
别名 | R7227, 丹诺普韦, ITMN-191, RG7227, RO5190591 |
分子量 | 731.83 |
分子式 | C35H46FN5O9S |
CAS No. | 850876-88-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 133 mg/mL (181.7 mM)
Ethanol: 133 mg/mL (181.7 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 1.3664 mL | 6.8322 mL | 13.6644 mL | 34.1609 mL |
5 mM | 0.2733 mL | 1.3664 mL | 2.7329 mL | 6.8322 mL | |
10 mM | 0.1366 mL | 0.6832 mL | 1.3664 mL | 3.4161 mL | |
20 mM | 0.0683 mL | 0.3416 mL | 0.6832 mL | 1.708 mL | |
50 mM | 0.0273 mL | 0.1366 mL | 0.2733 mL | 0.6832 mL | |
100 mM | 0.0137 mL | 0.0683 mL | 0.1366 mL | 0.3416 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Danoprevir 850876-88-9 Microbiology/Virology Proteases/Proteasome HCV Protease SARS-CoV RO 5190591 R7227 Inhibitor 丹诺普韦 SARS coronavirus Hepatitis C virus R-7227 ITMN-191 HCV ITMN 191 R 7227 RG 7227 RG-7227 RG7227 ITMN191 inhibit RO-5190591 RO5190591 inhibitor